Logo do repositório
 
Publicação

Next-Generation Sequencing in Breast Cancer Management

dc.contributor.authorBatista, Marta Vaz
dc.contributor.authorAlpuim Costa, Diogo
dc.contributor.authorBorralho, Paula
dc.contributor.authorBraga, Sofia
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblKarger
dc.date.accessioned2023-01-12T22:16:55Z
dc.date.available2023-01-12T22:16:55Z
dc.date.issued2021-08-16
dc.descriptionPublisher Copyright: © 2021 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).
dc.description.abstractThe clinicopathological breast cancer subtypes are used in clinical practice to better anticipate biological behaviour and guide systemic treatment strategy. In the adjuvant setting, genomic assay recurrence scores became widely available for luminal-like disease. Recently, next-generation sequencing (NGS) platforms have been used, essentially, in more advanced disease setting, in situations refractory to conventional treatment, or even in rare cancers for which there are no established treatment guidelines. Moreover, subpopulations of cancer cells with unique genomes within the same patient may exist across different regions of a tumour or evolve over time, which is called intratumoural heterogeneity. We herein report a case of a 38-year-old woman with breast cancer whose primary and metastatic disease exhibited discordant expression of hormone receptors, with the former being positive and the latter negative. Furthermore, the NGS analysis revealed slight and dynamic changes of mutational profiles between different metastatic lesions, potentially impacting breast cancer management and prognosis. These alterations may reflect tissular and temporal changes in tumour subclones and may also be due to the selective pressure caused by antineoplastic treatment. The use of genomic analyses in order to improve cancer treatment has been studied prospectively with encouraging results. The widespread use of NGS tests in clinical practice also creates new challenges. The most relevant may be to know which genomic alterations detected should be valued and how they should be targeted.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent8
dc.format.extent784551
dc.identifier.doi10.1159/000517441
dc.identifier.issn1662-6575
dc.identifier.otherPURE: 33775295
dc.identifier.otherPURE UUID: 257cbd8c-6179-472f-b759-765647c33933
dc.identifier.otherScopus: 85113936709
dc.identifier.otherWOS: 000692155100079
dc.identifier.urihttp://hdl.handle.net/10362/147440
dc.identifier.urlhttps://www.scopus.com/pages/publications/85113936709
dc.language.isoeng
dc.peerreviewedyes
dc.subjectBreast cancer in young
dc.subjectCase report
dc.subjectMetastatic breast cancer
dc.subjectNext-generation sequencing
dc.subjectOncology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleNext-Generation Sequencing in Breast Cancer Managementen
dc.title.subtitleA Case Report of Genomic Tumour Evolution over Timeen
dc.typejournal article
degois.publication.firstPage1212
degois.publication.issue2
degois.publication.lastPage1219
degois.publication.titleCase Reports in Oncology
degois.publication.volume14
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
A carregar...
Miniatura
Nome:
517441.pdf
Tamanho:
766.16 KB
Formato:
Adobe Portable Document Format